Executed borrowings to fund working capital and research and development. Lenders are Mr. Fuminori Yoshida and Ms. Ikuko Yoshida, amounts of 340 hundred million yen and 175 hundred million yen respectively; repayment in full on December 30, 2026; unsecured; interest rate 0.0%. No impact on consolidated results for the fiscal year ending December 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4582","jir_company_name":"SymBio Pharmaceuticals Limited","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4582-20261029-01.pdf","jir_short_summary":"Executed borrowings to fund working capital and research and development. Lenders are Mr. Fuminori Yoshida and Ms. Ikuko Yoshida, amounts of 340 hundred million yen and 175 hundred million yen respectively; repayment in full on December 30, 2026; unsecured; interest rate 0.0%. No impact on consolidated results for the fiscal year ending December 2026.","jir_summary":"### Key Points of Financing\nThis report discloses new borrowings to secure funds necessary for business execution, including working capital and research and development expenses. The lenders are individuals, with amounts of 340 hundred million yen and 175 hundred million yen, both at an annual interest rate of 0.0%, repayable in a lump sum on the maturity date, unsecured. The execution and signing date is October 15, 2026, and the repayment date is December 30, 2026. It is stated that this matter will not affect consolidated results for the fiscal year ending December 2026.\n\n### Impact on Investors and Outlook\nThis is short-term financing, and while cash position fluctuations may occur as the repayment date approaches, the view is that there will be no impact on performance. The funds are intended for working capital and research and development, and can be interpreted as aimed at improving liquidity flexibility. The long-term effect on capital efficiency is unknown, so future disclosures should be monitored.","jir_financial_highlights":"Borrowing Amount: 340,000,000 yen (0.0% interest)\nBorrowing Amount: 175,000,000 yen (0.0% interest)\nRepayment Date: 2026-12-30 (New borrowing)","jir_category":"","jir_hashtags":"#SymBioPharmaceuticals, #NoticeOfFinancing","jir_key_figures":"Borrowing Amount: 340,000,000 yen (interest rate 0.0%)\nBorrowing Amount: 175,000,000 yen (interest rate 0.0%)\nRepayment Date: 2026-12-30","jir_meta_title":"SymBio Pharmaceuticals Limited - Notice of Financing | October 2026","jir_meta_description":"SymBio Pharmaceuticals Limited executed new borrowings to cover working capital and R&D expenses. Details of lenders, amounts, repayment date, and interest rate are provided; no impact on consolidated results for the fiscal year ending December 2026.","jir_og_title":"Notice of Financing | SymBio Pharmaceuticals Limited October 2026","jir_og_description":"SymBio Pharmaceuticals Limited executed new borrowings for working capital and R&D. Discloses repayment date, interest rate, and absence of collateral. No impact on results for the fiscal year.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60013,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-135943","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n